MET and breast carcinoma: A recent study in preclinical breast cancer models provided evidence that a combination of pan-HER inhibitors with MET inhibitors (including tepotinib) may help overcome HER2 inhibitor resistance among patients with cooperating pan-HER and MET dysregulation (63).